KRAS and cancer: In murine models of PDAC with Kras and Tp53 mutations, Smad4 functionally interacts with Tp53 and Kras. Its inactivation reduces metastatic potential but increases cancer cell proliferation compared to the heterozygous deletion of Smad4 alone [298].